KOD · Kodiak Sciences Inc.
$37.50
+0.44 (+1.19%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had cash and cash equivalents of $125.9 million. We have incurred net losses and negative cash flows from operations since inception. We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.33B
Shares
62.85M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $2,725,068 |
| John Borgeson | Executive Vice President, Chief Financial Officer and Secretary | $1,679,701 |
| Jason Ehrlich | M.D., FormerChief Medical Officer and Chief Development Officer | $1,399,888 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $2,999,421 |
| Jason Ehrlich | M.D., FormerChief Medical Officer and Chief Development Officer | $1,625,797 |
| John Borgeson | Executive Vice President, Chief Financial Officer and Secretary | $1,507,502 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $113,371,207 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $27,946,551 |
| John Borgeson | Executive Vice President and Chief Financial Officer | $27,871,802 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $8,942,761 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $3,056,247 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $2,936,607 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $17,642,007 |
| Jason Ehrlich | M.D., ChiefMedical Officer and Chief Development Officer | $7,716,165 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $6,223,183 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | Chief Executive Officer and Chairman of the Board | $5,896,743 |
| Jason Ehrlich | M.D., Ph.D. Chief Medical Officer and Chief Development Officer | $3,745,287 |
| John Borgeson | Senior Vice President and Chief Financial Officer | $2,112,538 |